Observational studyMovement disorders : official journal of the Movement Disorder Society2016
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
Observational study in Movement disorders : official journal of the Movement Disorder Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 63 citations in OpenAlex.
- Study of blood linear RNA nominates CD55 and DLD as early-stage biomarkers for Parkinson's disease.Brain : a journal of neurology · 2026Article
- Evaluating language model embeddings for Parkinson's disease cohort harmonization using a novel manually curated variable mapping schema.Scientific reports · 2025Article
- Multi-omics machine learning classifier and blood transcriptomic signature of Parkinson's disease.Research square · 2025Article
- New diagnostic and staging framework applied to established PD in the BioFIND cohort.NPJ Parkinson's disease · 2025Article
- Sex differences in peripheral and central dysregulation of the kynurenine pathway in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson's disease.Scientific reports · 2024Article
- Transcriptional pathobiology and multi-omics predictors for Parkinson's disease.bioRxiv : the preprint server for biology · 2024Article
- Learning Phenotypic Associations for Parkinson's Disease with Longitudinal Clinical Records.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2024Article
- Elevated ApoE, ApoJ and lipoprotein-bound α-synuclein levels in cerebrospinal fluid from Parkinson's disease patients - Validation in the BioFIND cohort.Parkinsonism & related disorders · 2023Article
- Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.Translational neurodegeneration · 2023Article
- The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson's disease data.NPJ Parkinson's disease · 2023Article
- Myeloperoxidase and Advanced Oxidation Protein Products in the Cerebrospinal Fluid in Women and Men with Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2022Article
- Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation.Molecular neurobiology · 2022Article
- Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ´s disease.Clinical parkinsonism & related disorders · 2022Article
- Comprehensive subtyping of Parkinson's disease patients with similarity fusion: a case study with BioFIND data.NPJ Parkinson's disease · 2021Article
- Peripheral Klotho and Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2021Article
- A rapid α-synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy.Annals of clinical and translational neurology · 2021Article
- Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study.Journal of Parkinson's disease · 2021Article
- Prevalence and Relationship of Rest Tremor and Action Tremor in Parkinson's Disease.Tremor and other hyperkinetic movements (New York, N.Y.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 12 institutions in 1 country.
Funding
Abstract
backgroundIdentifying PD-specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well-characterized, clinically typical, moderate to advanced PD cohorts is critically needed.
methodsBioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross-sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites.
resultsWe present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls.
conclusionOur cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.